Covidien To Separate $2B Pharmaceuticals Unit
Health care products company Covidien PLC will spin off its $2 billion pharmaceuticals business into a stand-alone public company to help the new entity better compete in the growing pain management...To view the full article, register now.
Already a subscriber? Click here to view full article